- Home
- CISS vs CANF Comparison
CISS vs CANF Comparison
Compare CISS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | CANF |
|---|---|---|
| Founded | 2022 | 1994 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISS | CANF |
|---|---|---|
| Price | $0.25 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 875.3K | ★ 19.6M |
| Earning Date | 11-18-2025 | 11-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,613,149.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.28 |
| 52 Week High | $11.52 | $2.33 |
Technical Indicators
Market Signals| Indicator | CISS | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 15.99 | 31.65 |
| Support Level | $1.76 | $0.31 |
| Resistance Level | $1.94 | $0.33 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 0.97 | 0.71 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).